By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Signal Genetics has filed an amended lawsuit against Med BioGene, adding Precision Therapeutics as a defendant in a case it brought earlier this month to the Supreme Court for the County of New York.

Signal has accused Vancouver, British Columbia-based Med BioGene with fraud and Pittsburgh-based Precision Therapeutics with tortious interference in the amended complaint filed yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.